Syndrome of inappropriate antidiuretic hormone secretion and cerebral/renal salt wasting syndrome: similarities and differences. by �떊�옱�씪 & �삤吏��쁺
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PEDIATRICS
MINI REVIEW ARTICLE
published: 22 January 2015
doi: 10.3389/fped.2014.00146
Syndrome of inappropriate antidiuretic hormone secretion
and cerebral/renal salt wasting syndrome: similarities and
differences
JiYoung Oh and Jae Il Shin*
Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, South Korea
Edited by:
Jacqueline Ho, Children’s Hospital of
Pittsburgh of University of Pittsburgh
Medical Center, USA
Reviewed by:
Jakub Zieg, Charles University in
Prague, Czech Republic
Michael L. Moritz, Children’s Hospital
of Pittsburgh of University of
Pittsburgh Medical Center, USA
John Maesaka,Winthrop-University
Hospital, USA
*Correspondence:
Jae Il Shin, Department of Pediatrics,
Severance Children’s Hospital, Yonsei
University College of Medicine, 50
Yonsei-ro, Seodaemun-gu, C.P.O. Box
8044, Seoul 120-752, South Korea
e-mail: shinji@yuhs.ac
Hyponatremia (sodium levels of <135 mEq/L) is one of the most common electrolyte
imbalances in clinical practice, especially in patients with neurologic diseases. Hypona-
tremia can cause cerebral edema and brain herniation; therefore, prompt diagnosis and
proper treatment is important in preventing morbidity and mortality. Among various causes
of hyponatremia, diagnosing syndrome of inappropriate antidiuretic hormone secretion
(SIADH) and cerebral/renal salt wasting syndrome (C/RSW) is difficult due to many sim-
ilarities. SIADH is caused by excess of renal water reabsorption through inappropriate
antidiuretic hormone secretion, and fluid restriction is the treatment of choice. On the other
hand, C/RSW is caused by natriuresis, which is followed by volume depletion and negative
sodium balance and replacement of water and sodium is the mainstay of treatment. Deter-
minating volume status in hyponatremic patients is the key point in differential between
SIADH and C/RSW. However, in most situations, differential diagnosis of these two dis-
eases is difficult because they overlap in many clinical and laboratory aspects, especially
to assess differences in volume status of these patients. Although distinction between
the SIADH and C/RSW is difficult, improvement of hypouricemia and an increased frac-
tional excretion of uric acid after the correction of hyponatremia in SIADH, not in C/RSW,
may be one of the helpful points in discriminating the two diseases. In this review, we
compare these two diseases regarding the pathophysiologic mechanisms, diagnosis, and
therapeutic point of view.
Keywords: hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, cerebral/renal salt wasting
syndrome, volume status, fractional excretion of urate
INTRODUCTION
Hyponatremia, defined by sodium levels of <135 mEq/L, is one
of the common electrolyte imbalances in clinical practice, espe-
cially among patients with neurologic diseases (1). Prevalence of
hyponatremia is approximately 15–30% in hospitalized patients,
both children and adults, and 1–8% in outpatient clinic setting
(2). Acute hypoosmolality caused by serum sodium levels of 110–
120 mEq/L can cause cerebral edema and herniation (3–5). After
this osmotic insult, the adaptation mechanism of losing the elec-
trolytes and organic osmolytes in brain tissue facilitates restoration
of the brain volume (6, 7). This mechanism is known as“‘osmoreg-
ulation” (8, 9). However, correcting sodium levels too fast for
the brain tissue to adapt, especially in patients with more vul-
nerable brain tissue due to neurologic disorders, can impair this
osmoregulatory mechanism (9). Therefore, patients in these situ-
ations present brain deterioration that is more serious and have
show increased mortality rates (4, 9). Thus, rapid diagnosis of
hyponatremia is important in preventing morbidity and mortal-
ity in patient management, especially in neurologic intensive care
settings.
Among various causes of hyponatremia, the diagnoses of
the syndrome of inappropriate antidiuretic hormone secretion
(SIADH) and cerebral/renal salt wasting syndrome (C/RSW) are
still confusing due to many similarities. According to one ret-
rospective study of electrolyte disturbances in 195 children with
acute central nervous system (CNS) diseases, 20 (10.3%) children
showed hyponatremia, 7 of them were diagnosed with SIADH,
and the other 9 with cerebral salt wasting syndrome (CSW) (1).
Although it may be difficult to distinguish between the two dis-
eases, it is important to do so since the treatment of the two diseases
differ in many aspects (10). In this review, we would like to com-
pare these two diseases, which have many differences related to the
pathophysiologic mechanisms, diagnosis, and therapeutic points
of view despite the similarities.
DEFINITIONS AND PATHOPHYSIOLOGIC MECHANISMS OF
SIADH
SIADH is a disease categorized as hypo-osmolar hyponatremia;
small amount of volume expansion is caused by excess of
renal water reabsorption through inappropriate antidiuretic hor-
mone (ADH) secretion (11). Before the diagnosis of SIADH,
other diseases such as dysfunctions of heart, liver and kidneys,
adrenal insufficiency, and hypothyroidism, should be excluded.
Excessive ADH secretion causes water retention by increasing
water permeability in the renal collecting duct (12). Conse-
quently, the increased glomerular filtration rate (GFR) due to the
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volume expansion and vasodilating effect of increased circulat-
ing atrial/brain natriuretic peptides can increase sodium excretion
but there is also decreased tubular transport of sodium due to
unknown mechanism (12, 13). In addition, natriuretic peptides
are released primarily due to vasopressin stimulation (14) and, sec-
ondarily due to overfilling of the plasma volume by homeostatic
mechanisms (15). Increased pressure in the glomerular capillaries
and decreased plasma renin and aldosterone secretion can lead to
natriuresis by increasing GFR and blocking sodium reabsorption
in the collecting duct (14–16).
DEFINITIONS AND PATHOPHYSIOLOGIC MECHANISMS OF
C/RSW
C/RSW is another important disease category causing hypona-
tremia, characterized by volume depletion and negative sodium
balance. Peters et al. first described C/RSW in a report of three
patients with neurogenic diseases and hyponatremia (17). Follow-
ing the original description of SIADH by Schwartz et al. in 1957,
the term C/RSW had not been used for 20 years (12). Then, in
1981, Nelson et al. studied hyponatremia in patients undergoing
neurosurgery, and re-established interest in C/RSW (18). In that
journal, Nelson et al. determined blood volume by gold standard
radioisotope dilution methods and demonstrated a large number
of neurosurgical patients to be volume depleted with high uri-
nary sodium excretion that were very consistent with salt wasting
(18). Although C/RSW has also been considered to be caused by
sequential complications of CNS diseases (19–21), some reports
show that it could occur in patients without CNS diseases; there-
fore, it is recently referred to as renal salt wasting (RSW) (22, 23).
As a result of these studies, we agree with changing CSW to RSW
because CSW would not be considered in patients without cerebral
disease, the prevalence of which has yet to be determined.
The pathophysiology and mechanisms of C/RSW are not com-
pletely understood, nevertheless, there is general agreement that
the kidneys are unable to conserve sodium leading to variable
degrees of reduction in extracellular volume (ECV) depending the
extent of the defect in sodium transport and salt intake. In addi-
tion, the patient must also have a normally functioning kidney and
hypothalamic–pituitary–adrenal axis in order to be diagnosed as
C/RSW (17).
This syndrome could be explained with two main hypotheses
(4, 24,25): decreased sympathetic outflow to the kidney and ampli-
fication of the circulating natriuretic peptide, particularly brain
natriuretic peptide (24–26). Sympathetic tone plays an important
role in the kidney in sodium and water absorption at proximal
tubules and releasing renin at the juxtaglomerular epithelioid
cells (25, 27). Therefore, theoretically, renin–aldosterone levels
are not increased due to reduced sympathetic tone in the kidney
despite the volume depletion in C/RSW patients (16), but renin–
aldosterone levels have been reported to be high in salt wasting
(22). The patient with C/RSW initially loses sodium but eventu-
ally reaches a steady state where sodium excretion matches sodium
intake, and urinary sodium can be low despite having salt wasting.
In addition, increased natriuretic peptides induce natriuresis by
increasing GFR and preventing sodium reabsorption in the col-
lecting duct (28, 29). Also, natriuretic peptides could inhibit the
action of aldosterone, antagonize the arginine vasopressin (AVP)
effects and reduce sympathetic outflow (16,24,26). However,Mae-
saka et al. reported that natriuretic peptides were found to be low
in a volume depleted patient with RSW and suggested their contri-
bution to RSW is not supported by their modest effect on sodium
and other solute transport in the proximal tubules (22, 23).
If ECV is decreased due to C/RSW, the baroreceptors are trig-
gered and ADH is secreted to restore intravascular volume. The
stimulus for ADH secretion by the reduced ECV is more potent
than the osmolar effect on ADH secretion, so the patient remains
hyponatremic despite the hypoosmolality. This defines the appro-
priateness of ADH secretion in C/RSW and why saline can remove
the volume stimulus for ADH secretion and allow the hypoosmo-
lality to inhibit ADH secretion, increase free water excretion and
correct the hyponatremia.
SIADH AND C/RSW: SIMILARITIES AND DIFFERENCES
Distinguishing between SIADH and C/RSW is important since
the proper treatment for each disease is different, and erroneous
diagnosis could endanger the patient. However, it is difficult to
distinguish the two diseases because many clinical symptoms and
laboratory findings overlap. Hyponatremia is a common finding
of both SIADH and C/RSW, but the most important difference
between the two diseases is the patient’s volume status. SIADH
tends to be euvolemic or slightly hypervolemic, whereas C/RSW
tends to be hypovolemic (13, 24). Patients with SIADH do not
present overt hypervolemic signs clinically, since one-third of the
retention fluid remains in the extracellular space (13). Therefore, it
is difficult to distinguish between the two diseases with only clinical
symptoms and physical examinations (e.g., edema or neck vein dis-
tension), measurements of blood pressure, or pulse rate according
to posture change. There have been some methods for the direct
estimation of circulating blood volume by central venous catheter
(measurement of central venous pressure) or Swan–Ganz catheter
(measurement of pulmonary capillary wedge pressure) in patients
without cardiac or pulmonary diseases (4, 13, 30). However, CVP
determinations do not accurately determine the volume status
of patients when compared to gold standard radioisotope dilu-
tion methods, and there is no exact and easily applicable method,
which can be used to define volume status in children.
In addition, urine electrolytes can be used to evaluate volume
status (31, 32). Generally, it is known to be helpful diagnosing
SIADH when the patient exhibits urinary sodium and chloride
excretion increased more than 30 mmol/L and fractional excre-
tions of sodium and chloride more than 0.5% (33). In SIADH
patients with water retention, hypertension or catecholamine-
induced vasoconstriction can also induce aggressive natriuresis
temporarily, and therefore measuring mass balance of urinary
electrolytes over a few days may be more helpful to make a decision
(24, 34). Unfortunately, there is no gold standard cut-off value of
urinary sodium excretion to distinguish the two diseases.
Although laboratory findings such as elevated hematocrit,
plasma blood urea nitrogen (BUN), or albumin level might reflect
low effective blood volume in C/RSW (13, 33, 35), it may be
difficult to evaluate volume status accurately. Serum uric acid
levels are generally decreased and fractional excretions of uric
acid (FEUrate) are increased both in SIADH and C/RSW (12, 33,
36), although the mechanisms are not clear. Normal value of the
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FEUrate in euvolemic patients is about 10% and is reduced (usu-
ally <5%) in hypovolemic patients (37, 38). In most SIADH and
C/RSW patients, the level of FEUrate is more than 10%. Maesaka
et al. noted that hypouricemia and an increased FEUrate improve
in SIADH, but not in C/RSW after the correction of hyponatremia
(23, 37, 39). This might be associated with impaired sodium-
urate-co-transporter in the proximal tubule itself in C/RSW. The
FEUrate is suggested that it could be used in the algorithm to dis-
tinguish SIADH from C/RSW (22, 23). However, an exact value
and pathophysiologic mechanisms of decreased serum uric acid
level in pediatric patients remain elusive.
Although not tested in children, one recent report demon-
strated that bioimpedance spectroscopy showed a higher level of
agreement with clinical body fluid estimation than physical exami-
nation in adults with hyponatremia, suggesting that bioimpedance
spectroscopy could replace physical examination for estimating
body fluid status in hyponatremia (40). Because bioimpedance
spectroscopy is also used to measure hydration status in children
receiving hemodialysis (41), it would be interesting to study if this
method could be useful in determining the volume status in chil-
dren with hyponatremia in the future. However, special attention
should be paid utilization of bioimpedance is most effective when
volumes are determined at two time intervals where the changes
noted between both points are made.
TREATMENT
Because hyponatremia is poorly tolerated in patients with C/RSW
diseases, and even a small decrease in serum sodium can aggravate
vasogenic cerebral edema (42), it should be rapidly recognized and
managed promptly. Vasogenic edema is accumulating the protein-
rich fluid to the extracellular space resulted from destruction of
the blood–brain barrier due to increased vascular permeability
(43–46).
Three percent NaCl should be administered for acute symp-
tomatic hyponatremia. Excessive correction of chronic hypona-
tremia should be avoided as it can result in osmotic demyelination
(10, 47). Though it is rare, osmotic demyelination is a serious and
fatal complication that can cause aggressive neurologic deficit such
as seizure, quadriplegia, coma, and even death (6, 47, 48).
Simple fluid restriction is recommended for the treatment
of hyponatremia in uncomplicated SIADH (11, 49). Isotonic
saline is not usually effective in increasing serum sodium lev-
els in SIADH, because water will be retained and sodium will
be excreted in urine, causing possible aggravation of hypona-
tremia. Hypertonic saline can increase serum sodium levels, but
the response will partially dissipate over time and therefore, oral
salt tablets with loop diuretics can be considered as a treatment
of hyponatremia caused by SIADH (50). Vasopressin receptor
antagonists (vaptans) emerged as a new class of drugs for the
treatment of euvolemic and hypervolemic hyponatremia such as
SIADH in adults (51). Although there have been scarce stud-
ies of data research on the use of vaptans in children (52, 53),
Jones et al. showed that intravenous conivaptan was effective for
increasing serum sodium levels and might be a potential adju-
vant to enhance diuresis in children with cardiac disease (52) and
Horibata et al. reported oral tolvaptan improved the condition of
6-year-old boy with the loop diuretic-resistant congestive cardiac
failure without hypernatremia, deterioration of vital signs, and
significant complications (53). The common side effects of vap-
tans are thirst and increased urination (2, 54). Recently, one case
report of over-correction of hyponatremia with development of
severe hypernatremia and demyelination with usage of vaptan was
published (2, 55). In addition, one report was reported that long
term usage of tolvaptan was resulted in severe hepatotoxicity in
a patient with autosomal dominant polycystic kidney disease (2,
56). Some reports suggested contraindications of vaptan (57, 58).
Vaptan therapy is absolutely contraindicated for patients in hypo-
volemic hyponatremia, because these patients already experienced
loss of water and sodium that exceeded hemodynamic compen-
sation and renal function (57, 58). Therefore, safety concerns and
clinical trials regarding vaptan use in children with SIADH will be
necessary in the future.
The treatment purpose of C/RSW is to restore decreased serum
sodium levels and intravascular volume due to natriuresis and
diuresis and normal saline is frequently used as an initial fluid (4,
30, 59). If the patient with salt wasting becomes euvolemic with
saline, the hyponatremia should be corrected in a short period of
time. If it does not, there should be a question of the accuracy
of the diagnosis. At the start of the treatment, it might be safer
to use hypertonic saline if the patient has symptomatic hypona-
tremia and then switch to isotonic saline, which should eliminate
the more potent volume stimulus for ADH secretion. To make
strengthen the diagnosis of salt wasting, testing for excretion of
diluted urines may be useful. Once euvolemia is achieved, the
degree of hyponatremia should be re-evaluated. If serum sodium
levels are severely decreased (<125 mEq/L) or a large volume of
intravenous fluids is required to maintain euvolemia, intravenous
hypertonic saline can also be used (4). A hypertonic 3% NaCl infu-
sion can be titrated with a 0.9% NaCl infusion to obtain the desired
sodium concentration to maintain appropriate serum sodium (44,
60), or alternatively, mineralocorticoids can be used to augment
both serum sodium concentration and intravascular volume (61–
64). Oral salt supplementation can be used in a stable patient with
CNS disease and C/RSW.
CONCLUSION
Because SIADH and C/RSW have many similarities, differential
diagnosis is very difficult in patients with hyponatremia, espe-
cially in those with CNS diseases. Nevertheless, it is also important
to distinguish between SIADH and C/RSW since the treatment of
them differ in many aspects. Volume status of the patients, though
it may be difficult to evaluate in the clinical setting, serum uric
acid levels and FEUrate after correcting hyponatremia, and the
degree of fractional excretions of sodium may be useful in dif-
ferentiating between the two diseases. Therefore, further studies
regarding pathophysiologic mechanisms of diseases and devel-
opment of diagnostic tools to determine exact volume status is
necessary in the future.
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